Boundless Bio, Inc. financial data

Symbol
BOLD on Nasdaq
Industry
Pharmaceutical Preparations
Location
9880 Campus Point Drive, Suite 120, San Diego, CA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 22.3M shares
Common Stock, Shares, Outstanding 22.3M shares
Common Stock, Value, Issued 2K USD
Weighted Average Number of Shares Outstanding, Basic 22M shares +1726%
Weighted Average Number of Shares Outstanding, Diluted 22M shares +1726%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 14.7M USD +33%
General and Administrative Expense 4.66M USD +61.4%
Operating Income (Loss) -19.4M USD -38.9%
Nonoperating Income (Expense) 2.42M USD +54.6%
Net Income (Loss) Attributable to Parent -17M USD -36.9%
Earnings Per Share, Basic -0.77 USD/shares +92.5%
Earnings Per Share, Diluted -0.77 USD/shares +92.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 31.4M USD -24.1%
Cash, Cash Equivalents, and Short-term Investments 179M USD
Assets, Current 183M USD
Property, Plant and Equipment, Net 3.74M USD
Operating Lease, Right-of-Use Asset 754K USD
Assets 188M USD
Accounts Payable, Current 1.69M USD
Employee-related Liabilities, Current 2.05M USD
Liabilities, Current 8.96M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax -64K USD
Retained Earnings (Accumulated Deficit) -169M USD
Stockholders' Equity Attributable to Parent 179M USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 179M USD
Liabilities and Equity 188M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -15.8M USD -30.5%
Net Cash Provided by (Used in) Financing Activities -924K USD -3081%
Net Cash Provided by (Used in) Investing Activities 18.1M USD -18.2%
Common Stock, Shares Authorized 700M shares
Common Stock, Shares, Issued 22.3M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.44M USD -85.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 31.9M USD -23.8%
Depreciation 263K USD +11%
Payments to Acquire Property, Plant, and Equipment 83K USD -3.49%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -17M USD -37.1%
Property, Plant and Equipment, Gross 6.99M USD
Operating Lease, Liability, Current 837K USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 70M shares
Operating Lease, Payments 700K USD 0%
Additional Paid in Capital 348M USD
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 2.14M USD +130%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares